Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hua Da Trading, Inc.
WARNING LETTER
•Hua Da Trading, Inc.•December 20, 2023

FDA WARNING_LETTER - Hua Da Trading, Inc. - December 20, 2023

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

The FDA issued a Warning Letter to Daniel Zeng regarding the product "WeFun" sold on eshoponlineusa.com. An FDA review from July-December 2023 and laboratory analysis confirmed "WeFun" contains undeclared sildenafil, a PDE-5 inhibitor and active ingredient in the prescription drug Viagra.

This makes "WeFun" an unapproved new drug under sections 505(a) and 301(d) of the FD&C Act, as sildenafil was not marketed as a dietary supplement before Viagra's approval in 1998. The product is also misbranded under section 502 of the FD&C Act and sold in violation of section 301(a). Misbranding violations include failure to bear adequate directions for use (502(f)(1)), false or misleading labeling due to undeclared sildenafil (502(a)), and lack of adequate warnings (502(f)(2)). Sildenafil can dangerously lower blood pressure, especially for individuals on nitrates.

The letter also expresses concern about other products sold on the website, such as "BLACK ANT KING," "BIGGER LONGER," "Germany Black Gorilla," and "Rhino" products, which FDA has previously found to contain undeclared sildenafil and/or tadalafil, and "Royal Honey," previously found to contain undeclared PDE-5 inhibitors.

The company must

Company
Hua Da Trading, Inc.
Inspection Date
December 20, 2023
Product Type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Jill P. Furman (Director)
Open in Dashboard

ID · 22cf35a7-028a-4ac7-a3bd-c72e8be73e40

Violation Codes10
21 U.S.C. 353(b)(1)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 35221 U.S.C. 321(ff)(3)(B)(i)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21 U.S.C. 352(f)(1)21 CFR 201.521 U.S.C. 353(b)(1)(A)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.